Apogee Therapeutics (Apogee Therapeutics) Stock Based Compensation : $9.02 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Apogee Therapeutics Stock Based Compensation?

Apogee Therapeutics's Stock Based Compensation for the three months ended in Mar. 2024 was $4.19 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was $9.02 Mil.

Apogee Therapeutics Stock Based Compensation Historical Data

The historical data trend for Apogee Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apogee Therapeutics Stock Based Compensation Chart

Apogee Therapeutics Annual Data

Trend

Dec22

Dec23

Stock Based Compensation

2.14

6.10

Apogee Therapeutics Quarterly Data
	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Stock Based Compensation	Get a 7-Day Free Trial			1.27	1.11	1.51	2.21	4.19

Apogee Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.02 Mil.

Apogee Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Apogee Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Apogee Therapeutics (Apogee Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apogee Therapeutics Inc (NAS:APGE) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

N/A

Address

221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453

Website

https://www.apogeetherapeutics.com

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.

Executives

Mark C. Mckenna	director	400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Nimish P Shah	director	7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jane Henderson	officer: Chief Financial Officer	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Peter Evan Harwin	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jones William A Jr	director	NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Fairmount Funds Management Llc	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Michael Thomas Henderson	director, officer: Chief Executive Officer	421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p.	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p.	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jennifer A. Fox	director	C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Andrew Gottesdiener	director	3340 HILLVIEW AVE, PALO ALTO CA 94304
Fairmount Healthcare Co-invest Ii L.p.	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Carl Dambkowski	officer: Chief Medical Officer	221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM MA 02453